MX2018009247A - Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. - Google Patents

Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.

Info

Publication number
MX2018009247A
MX2018009247A MX2018009247A MX2018009247A MX2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A
Authority
MX
Mexico
Prior art keywords
immunotherapies
histone deacetylase
enhancing
deacetylase inhibitors
inhibitors
Prior art date
Application number
MX2018009247A
Other languages
English (en)
Inventor
Pili Roberto
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2018009247A publication Critical patent/MX2018009247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones que incluyen combinaciones de inhibidores de histona desacetilasa (HDAC) de clase I e inhibidores de proteína de muerte celular programada (PD-1) para mejorar la actividad antiumor. Además se describen métodos para administrar estas composiciones como inmunoterapias para suprimir células T reguladoras en el carcinoma de célula renal.
MX2018009247A 2016-01-28 2017-01-27 Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. MX2018009247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288121P 2016-01-28 2016-01-28
PCT/US2017/015389 WO2017132536A1 (en) 2016-01-28 2017-01-27 Use of histone deacetylase inhibitors for enhancing immunotherapies

Publications (1)

Publication Number Publication Date
MX2018009247A true MX2018009247A (es) 2019-03-11

Family

ID=58010402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009247A MX2018009247A (es) 2016-01-28 2017-01-27 Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.

Country Status (13)

Country Link
US (1) US10813919B2 (es)
EP (1) EP3407913A1 (es)
JP (1) JP2019503386A (es)
KR (1) KR20180104122A (es)
CN (1) CN108883179A (es)
AU (1) AU2017211383A1 (es)
BR (1) BR112018015291A2 (es)
CA (1) CA3013047A1 (es)
IL (1) IL260765A (es)
MX (1) MX2018009247A (es)
RU (1) RU2018130831A (es)
WO (1) WO2017132536A1 (es)
ZA (1) ZA201805066B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN110300599A (zh) 2016-12-07 2019-10-01 艾吉纳斯公司 抗体和其使用方法
WO2018225063A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
SG10201900072VA (en) 2018-01-05 2019-08-27 Gnt Biotech & Medicals Corp A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
JP2021511293A (ja) * 2018-01-12 2021-05-06 ビラクタ セラピューティクス，インク． 細胞免疫療法で使用されるエピジェネティック修飾因子
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
CN112569360A (zh) * 2019-09-30 2021-03-30 中国医学科学院药物研究所 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5623747B2 (ja) 2006-12-27 2014-11-12 エモリー ユニバーシティ 感染症および腫瘍を処置するための組成物および方法
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
CA2980297A1 (en) 2015-03-20 2016-09-29 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
WO2017035453A1 (en) 2015-08-26 2017-03-02 The Johns Hopkins University Compositions and methods for treating solid tumors
EP3345002A4 (en) * 2015-09-02 2019-05-08 Syndax Pharmaceuticals Inc. SELECTION OF PATIENTS FOR POLYTHERAPY

Also Published As

Publication number Publication date
EP3407913A1 (en) 2018-12-05
RU2018130831A (ru) 2020-03-02
BR112018015291A2 (pt) 2018-12-18
AU2017211383A1 (en) 2018-08-16
RU2018130831A3 (es) 2020-04-23
CN108883179A (zh) 2018-11-23
WO2017132536A1 (en) 2017-08-03
KR20180104122A (ko) 2018-09-19
US10813919B2 (en) 2020-10-27
ZA201805066B (en) 2019-05-29
IL260765A (en) 2018-10-31
US20190030011A1 (en) 2019-01-31
CA3013047A1 (en) 2017-08-03
JP2019503386A (ja) 2019-02-07

Similar Documents

Publication Publication Date Title
MX2018009247A (es) Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.
MX2022002465A (es) Inhibidores de kras g12d.
MX2020005063A (es) Inhibidores de kras g12c.
MX2020005477A (es) Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
CY1123676T1 (el) Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων
ZA202007007B (en) Mcl-1 inhibitors
MX2018013983A (es) Inhibidores g12c de kras.
MX2020005701A (es) Células efectoras inmunitarias potenciadas y usos de las mismas.
MY197478A (en) Compositions and methods for inhibiting arginase activity
EA201790968A1 (ru) Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки
EA201992358A1 (ru) Тканеселективная экспрессия трансгена
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2021000299A (es) Preparados combinados para el tratamiento contra el cancer o infecciones.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
EA201592103A3 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
PH12019550027A1 (en) Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
MX2019006893A (es) Inhibidores heterociclicos de mct4.
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
EA201791933A1 (ru) Ингибирование активности olig2
ZA201901367B (en) Inhibition of olig2 activity
EA201991192A1 (ru) Фармацевтические композиции и способы лечения рака
MX2017015532A (es) Terapia de combinacion pac-1.
MX2014010714A (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2020011470A (es) Metodos de terapia genica.
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.